000258243 001__ 258243
000258243 005__ 20231004134645.0
000258243 0247_ $$2doi$$a10.1097/WNR.0000000000001917
000258243 0247_ $$2pmid$$apmid:37270842
000258243 0247_ $$2pmc$$apmc:PMC10234325
000258243 0247_ $$2ISSN$$a0959-4965
000258243 0247_ $$2ISSN$$a1473-558X
000258243 0247_ $$2altmetric$$aaltmetric:149549112
000258243 037__ $$aDZNE-2023-00589
000258243 041__ $$aEnglish
000258243 082__ $$a610
000258243 1001_ $$aHelf, Charlotte$$b0
000258243 245__ $$aSubthalamic nucleus deep brain stimulation induces nigrostriatal dopaminergic plasticity in a stable rat model of Parkinson's disease.
000258243 260__ $$a[Erscheinungsort nicht ermittelbar]$$bOvid$$c2023
000258243 3367_ $$2DRIVER$$aarticle
000258243 3367_ $$2DataCite$$aOutput Types/Journal article
000258243 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1687785893_14543
000258243 3367_ $$2BibTeX$$aARTICLE
000258243 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000258243 3367_ $$00$$2EndNote$$aJournal Article
000258243 520__ $$aDeep brain stimulation (DBS) of the subthalamic nucleus (STN) has been a highly effective treatment option for middle to late stage Parkinson's disease for decades. Though, the underlying mechanisms of action, particularly effects on the cellular level, remain in part unclear. In the context of identifying disease-modifying effects of STN-DBS by prompting cellular plasticity in midbrain dopaminergic systems, we analyzed neuronal tyrosine hydroxylase and c-Fos expression in the substantia nigra pars compacta (SNpc) and ventral tegmental area (VTA).We applied 1 week of continuous unilateral STN-DBS in a group of stable 6-hydroxydopamine (6-OHDA) hemiparkinsonian rats (STNSTIM) in comparison to a 6-OHDA control group (STNSHAM). Immunohistochemistry identified NeuN+, tyrosine hydroxylase+ and c-Fos+ cells within the SNpc and VTA.After 1 week, rats in the STNSTIM group had 3.5-fold more tyrosine hydroxylase+ neurons within the SNpc (P = 0.010) but not in the VTA compared to sham controls. There was no difference in basal cell activity as indicated by c-Fos expression in both midbrain dopaminergic systems.Our data support a neurorestorative effect of STN-DBS in the nigrostriatal dopaminergic system already after 7 days of continuous STN-DBS in the stable Parkinson's disease rat model without affecting basal cell activity.
000258243 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000258243 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000258243 650_7 $$08HW4YBZ748$$2NLM Chemicals$$aOxidopamine
000258243 650_7 $$0EC 1.14.16.2$$2NLM Chemicals$$aTyrosine 3-Monooxygenase
000258243 650_7 $$0VTD58H1Z2X$$2NLM Chemicals$$aDopamine
000258243 650_2 $$2MeSH$$aRats
000258243 650_2 $$2MeSH$$aAnimals
000258243 650_2 $$2MeSH$$aParkinson Disease: therapy
000258243 650_2 $$2MeSH$$aParkinson Disease: metabolism
000258243 650_2 $$2MeSH$$aSubthalamic Nucleus: metabolism
000258243 650_2 $$2MeSH$$aOxidopamine: toxicity
000258243 650_2 $$2MeSH$$aDeep Brain Stimulation
000258243 650_2 $$2MeSH$$aTyrosine 3-Monooxygenase: metabolism
000258243 650_2 $$2MeSH$$aDopamine: metabolism
000258243 650_2 $$2MeSH$$aSubstantia Nigra: metabolism
000258243 7001_ $$aKober, Maria$$b1
000258243 7001_ $$aMarkert, Franz$$b2
000258243 7001_ $$aLanto, Jennifer$$b3
000258243 7001_ $$aOverhoff, Leonie$$b4
000258243 7001_ $$aBadstübner-Meeske, Kathrin$$b5
000258243 7001_ $$0P:(DE-2719)9000306$$aStorch, Alexander$$b6$$udzne
000258243 7001_ $$aFauser, Mareike$$b7
000258243 773__ $$0PERI:(DE-600)2031485-1$$a10.1097/WNR.0000000000001917$$gVol. 34, no. 10, p. 506 - 511$$n10$$p506 - 511$$tNeuroreport$$v34$$x0959-4965$$y2023
000258243 8564_ $$uhttps://journals.lww.com/neuroreport/Fulltext/2023/06020/Subthalamic_nucleus_deep_brain_stimulation_induces.3.aspx
000258243 8564_ $$uhttps://pub.dzne.de/record/258243/files/DZNE-2023-00589.pdf$$yOpenAccess
000258243 8564_ $$uhttps://pub.dzne.de/record/258243/files/DZNE-2023-00589.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000258243 909CO $$ooai:pub.dzne.de:258243$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000258243 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9000306$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b6$$kDZNE
000258243 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000258243 9141_ $$y2023
000258243 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-09
000258243 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2022-11-09
000258243 915__ $$0LIC:(DE-HGF)CCBYNCND4$$2HGFVOC$$aCreative Commons Attribution-NonCommercial-NoDerivs CC BY-NC-ND 4.0
000258243 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-09
000258243 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000258243 915__ $$0StatID:(DE-HGF)0410$$2StatID$$aAllianz-Lizenz$$d2023-08-22$$wger
000258243 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNEUROREPORT : 2022$$d2023-08-22
000258243 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-22
000258243 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-22
000258243 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-22
000258243 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-08-22
000258243 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-22
000258243 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-08-22
000258243 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-08-22
000258243 9201_ $$0I:(DE-2719)5000014$$kAG Storch 2 Rostock$$lNon-Motor Symptoms in Parkinson's disease$$x0
000258243 980__ $$ajournal
000258243 980__ $$aVDB
000258243 980__ $$aUNRESTRICTED
000258243 980__ $$aI:(DE-2719)5000014
000258243 9801_ $$aFullTexts